Douglas Hanahan
In this article, we will explore the fascinating world of Douglas Hanahan. From its origins to its impact on modern life, Douglas Hanahan has played a crucial role in multiple aspects of society. This topic has not only captured the curiosity of academics and experts but has also generated massive interest among the general public. Over the next few pages, we will delve into the history, importance, and future of Douglas Hanahan, hoping to provide a deeper and more meaningful insight into this highly relevant topic today.
Douglas Hanahan | |
|---|---|
 Hanahan in 2017 at EPFL | |
| Born | 1951 (age 73–74) Seattle, Washington |
| Alma mater | Harvard University |
| Known for | "The Hallmarks of Cancer" "DH5-Alpha Cell" named after him |
| Scientific career | |
| Institutions | École polytechnique fédérale de Lausanne (EPFL) University of California, San Francisco |
Douglas Hanahan (born 1951)[1] is an American biologist, professor, and Director Emeritus of the Swiss Institute for Experimental Cancer Research at EPFL (École polytechnique Fédérale de Lausanne) in Lausanne, Switzerland. He is a Distinguished Scholar at the Lausanne branch of the Ludwig Institute for Cancer Research.
Education and early career
Hanahan received a bachelor's degree in physics from the Massachusetts Institute of Technology (MIT) in 1976 and earned his Ph.D. in biophysics from Harvard University in 1983 as a Harvard Society of Fellows member.[2]
He conducted research at Cold Spring Harbor Laboratory, first as a graduate student and later as a faculty member. During his tenure, he developed methodologies to facilitate the molecular cloning of genes in E. coli, a foundational tool in life sciences.[3]
Research
Hanahan pioneered the genetic engineering of transgenic mouse models to study human cancer. In collaboration with Judah Folkman, he discovered the “angiogenic switch,” a process that enables new blood vessel formation and facilitates tumor progression towards malignancy.[4]
Dr. Hanahan spent twenty-one years at the University of California San Francisco, in the UCSF Diabetes Center prior to EPFL in 2009. During that time (2000), Hanahan co-authored a seminal paper with Robert Weinberg entitled The Hallmarks of Cancer, which proposed a conceptual framework for understanding the complexity of cancer development.[5] This was followed by updated reviews in 2011[6] and 2022.[7]
He was instrumental in founding the Swiss Cancer Center Leman (SCCL), the first comprehensive cancer center in Switzerland. Hanahan also played a key role in developing the Agora Translational Cancer Research Center, a collaborative facility designed to advance cancer research and therapy.
Awards and honors
- 2025 Pezcoller Foundation Award in Cancer Research
- 2023 Elected to the Royal Society of London
- 2020 Distinguished Scholar, Ludwig Institute for Cancer Research
- 2014 Fellow of the AACR Academy
- 2014 AACR Lifetime Achievement Award in Cancer Research
- 2010 Elected Member, European Molecular Biology Association
- 2009 Elected Member, National Academy of Sciences
- 2008 Elected Member, National Academy of Medicine
- 2007 Elected Fellow, American Academy of Arts and Sciences
- 1993 Grand Prize for Biology, National Cancer Association of France
See also
References
- ^ "Biography 34: Doug Hanahan (1951 - )". Dolan DNA Learning Center. Cold Spring Harbor Laboratory. Retrieved 4 April 2011.
- ^ "Douglas Hanahan, PhD". Fellows of the AACR Academy. American Association for Cancer Research (AACR). Retrieved 28 March 2025.
- ^ Hanahan D (June 1983). "Studies on transformation of Escherichia coli with plasmids". Journal of Molecular Biology. 166 (4): 557–580. doi:10.1016/S0022-2836(83)80284-8. PMID 6345791.
- ^ Hanahan D, Folkman J (August 1996). "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis". Cell. 86 (3): 353–364. doi:10.1016/s0092-8674(00)80108-7. PMID 8756718.
- ^ Hanahan D, Weinberg RA (January 2000). "The hallmarks of cancer". Cell. 100 (1): 57–70. doi:10.1016/S0092-8674(00)81683-9. PMID 10647931.
- ^ Hanahan D, Weinberg RA (March 2011). "Hallmarks of cancer: the next generation". Cell. 144 (5): 646–674. doi:10.1016/j.cell.2011.02.013. PMID 21376230.
- ^ Hanahan D (January 2022). "Hallmarks of Cancer: New Dimensions". Cancer Discovery. 12 (1): 31–46. doi:10.1158/2159-8290.CD-21-1059. PMID 35022204.